Japan to Start Hunting Whales Again, Withdraws from Global Whaling Group

Agencies
December 26, 2018

Tokyo, Dec 26: Japan said Wednesday it is withdrawing from the International Whaling Commission and will resume commercial whaling next year, in a move expected to spark international criticism.

The announcement had been widely expected and comes after Japan failed in a bid earlier this year to convince the IWC to allow it to resume commercial whaling.

"We have decided to withdraw from the International Whaling Commission in order to resume commercial whaling in July next year," top government spokesman Yoshihide Suga told reporters.

"Commercial whaling... will be limited to Japan's territorial waters and exclusive economic zones. We will not hunt in the Antarctic waters or in the southern hemisphere," Suga added.

Tokyo has repeatedly threatened to pull out of the body, and has been regularly criticised for catching hundreds of whales a year for "scientific research" despite being a signatory to a moratorium on hunting the animals.

Suga said Japan would officially inform the IWC of its decision by the end of the year, which will mean the withdrawal comes into effect by June 30.

Leaving the IWC means Japanese whalers will be able to resume hunting in Japanese coastal waters of minke and other whales currently protected by the IWC.

But Japan will not be able to continue the so-called scientific research hunts in the Antarctic that it has been exceptionally allowed as an IWC member under the Antarctic Treaty.

'Fundamental reassessment'

The withdrawal means Japan joins Iceland and Norway in openly defying the IWC's ban on commercial whale hunting.

Japan has hunted whales for centuries, and the meat was a key source of protein in the immediate post-World War II years when the country was desperately poor.

But consumption has declined significantly in recent decades, with much of the population saying they rarely or never eat whale meat.

Whale hunting has become a rare thorny subject in Japan's otherwise largely amiable foreign policy, with international opposition only serving to make conservatives dig in deeper in support of the tradition.

Many members of Prime Minister Shinzo Abe's conservative Liberal Democratic Party are supporters of whaling, and he himself comes from a constituency where whale hunting remains popular.

Tokyo argues that whaling is an important part of Japan's traditions, and Suga said the withdrawal would allow fishermen to "pass our country's rich whaling culture onto the next generation."

In September, Tokyo sought to convince the IWC to allow it to resume commercial whaling, arguing that stocks of certain species were now sufficient to support renewed hunting.

But the bid failed, with strong opposition from anti-whaling nations -- led by Australia, the European Union and the United States.

'Out of step'

Activist groups slammed the decision, with Greenpeace calling it a "sneaky" announcement.

"The declaration today is out of step with the international community, let alone the protection needed to safeguard the future of our oceans and these majestic creatures," said Sam Annesley, executive director at Greenpeace Japan.

The IWC, established in 1946 to conserve and manage the world's whale and cetacean population, introduced a moratorium on commercial whaling in 1986.

Tokyo has long exploited a loophole allowing whales to be killed for "scientific research" and says it is trying to prove the population is large enough to sustain a return to commercial hunting.

It makes no secret of the fact that meat from the expeditions ends up on dinner tables.

"There have been no concessions from countries who only place importance on the protection of whales," Suga said.

"At the IWC general meeting in September this year, it became evident once again that those supporting the sustainable use of whale stocks and those supporting protection cannot co-exist, leading us to this conclusion."

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
March 15,2020

Tehran, Mar 15: Two hundred and thirty-four Indians stranded in coronavirus-hit Iran have arrived in India, External Affairs Minister S Jaishankar said on Sunday.

The batch comprises 131 students and 103 pilgrims, he said.

“234 Indians stranded in Iran have arrived in India; including 131 students and 103 pilgrims. Thank you Ambassador Dhamu Gaddam and @India_in_Iran team for your efforts. Thank Iranian authorities,” Jaishankar tweeted.

The third batch of Indians from Iran arrived early Sunday. A second batch of 44 Indian pilgrims had arrived from Iran on Friday.

Iran is one of the worst-affected countries by the coronavirus outbreak and the government has been working on plans to bring back Indians stranded there.

The first batch of 58 Indian pilgrims were brought back from Iran on Tuesday.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
August 3,2020

Manila, Aug 2: The number of COVID-19 cases in the Philippines has exceeded the 100,000 marks with a record 5,032 new infections registered on Sunday, the Health Ministry's data showed.

With the total cases now reaching 103,185, the spread of COVID-19 in the Southeast Asian nation is steeply rising. The daily growth rate just this Thursday set a record at over 3,800 cases, the next day there were nearly 4,000 new infections detected and on Saturday, over 4,800 cases were detected.

More than 65,000 people have recovered from the ailment, while 2,059 people have died.

The Philippines' epidemiological dynamic mirrors that of many Southeast Asian nations, where COVID-19 infections have only recently begun to climb. 

Most other nations in Europe and the Americas experienced an initial spread of the virus which later tailed off only to begin climbing again after easing of restrictions.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 4,2020

Jun 4: A malaria drug President Donald Trump took to try to prevent COVID-19 proved ineffective for that in the first large, high-quality study to test it in people in close contact with someone with the disease.

Results published Wednesday by the New England Journal of Medicine show that hydroxychloroquine was no better than placebo pills at preventing illness from the coronavirus.

The drug did not seem to cause serious harm, though -- about 40% on it had side effects, mostly mild stomach problems.

 “We were disappointed. We would have liked for this to work,” said the study leader, Dr. David Boulware, an infectious disease specialist at the University of Minnesota.

“But our objective was to answer the question and to conduct a high-quality study,” because the evidence on the drug so far has been inconclusive, he said.

Hydroxychloroquine and a similar drug, chloroquine, have been the subject of much debate since Trump started promoting them in March.

Hydroxychloroquine has long been used for malaria, lupus, and rheumatoid arthritis, but no large studies have shown it or chloroquine to be safe or effective for much sicker patients with coronavirus, and some studies have suggested the drugs may do harm.

Trump took a two-week course of hydroxychloroquine, along with zinc and Vitamin D, after two staffers tested positive for COVID-19, and had no ill effects, according to results of his latest physical released by his doctor Wednesday.

Federal regulators have warned against hydroxychloroquine's use except in hospitals and formal studies because of the risk of side effects, especially heart rhythm problems.

Boulware's study involved 821 people in the United States and Canada living with someone diagnosed with COVID-19 or at high risk of getting it because of their job -- doctors, nurses, ambulance workers who had significant exposure to a sick patient while not wearing full protective gear.

They were randomly assigned to get either the nutrient folate as a placebo or hydroxychloroquine for five days, starting within four days of their exposure. Neither they nor others involved in the research knew who was getting which pills.

After 14 days in the study, 12 per cent on the drug developed COVID-19 symptoms versus 14 per cent in the placebo group, but the difference is so small it could have occurred by chance, Boulware said.

“There's basically no effect. It does not prevent infection,” he said of the drug. Even if it were to give some slim advantage, “we'd want a much larger effect” to justify its use and risk of side effects for preventing illness, he said.

Results were no different among a subgroup of participants who were taking zinc or vitamin C, which some people believe might help make hydroxychloroquine more effective or fight the coronavirus.

There are some big caveats: The study enrolled people through the Internet and social media, relying on them to report their own symptoms rather than having them tracked in a formal way by doctors.

Participants were not all tested for the coronavirus but were diagnosed as COVID-19 cases based on symptoms in many cases. And not all took their medicines as directed.

The results “are more provocative than definitive,” and the drug may yet have prevention benefits if tried sooner or in a different way, Dr. Myron Cohen of the University of North Carolina at Chapel Hill wrote in a commentary in the journal.

Others were glad to see a study that had a comparison group and good scientific methods after so many weaker reports on hydroxychloroquine.

“This fits with everything else we've seen so far which suggests that it's not beneficial," said Dr. Peter Bach, director of a health policy center at Memorial Sloan Kettering Cancer Center in New York.

This study was in younger relatively healthy people, but the results “would make me very discouraged about trying to use this in older people” who are most vulnerable to serious illness from the coronavirus, Bach said.

“If it does work, it doesn't work very well.” Dr. Dan Culver, a lung specialist at the Cleveland Clinic, said there's still a chance that giving the drug sooner than four days after someone's exposure to the virus may help prevent illness.

But the study “takes 'home run' off the table” as far as hopes for the drug, he said.

The study was mostly funded by David Baszucki, founder of Roblox, a California-based game software company, and other private donors and the Minnesota university.

Boulware also is leading a study testing hydroxychloroquine for treating COVID-19. The study is finished and results are being analyzed now.

On Tuesday, the journal Lancet posted an “expression of concern” about a study it published earlier this month of nearly 15,000 COVID-19 patients on the malaria drugs that tied their use to a higher risk of dying in the hospital or developing a heartbeat problem.

Scientists have raised serious questions about the database used for that study, and its authors have launched an independent audit.

That work had a big impact: the World Health Organization suspended use of hydroxychloroquine in a study it is leading, and French officials stopped the drug's use in hospitals. On Wednesday, the WHO said experts who reviewed safety information decided that its study could resume.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.